加利福尼亚州将在2026年初 推出州立胰岛素 以降低居民成本 California to launch state-branded insulin in early 2026 to cut costs for residents.

加利福尼亚州正在推出自己的全州品牌的胰岛素,作为“加州”胰岛素市场销售,以提高居民的可负担性和可获得性。 California is launching its own state-branded insulin, marketed as "California" insulin, to increase affordability and accessibility for residents. 该方案是国家降低处方药成本的更广泛努力的一部分,它将通过选定的药店和保健服务提供者,以大幅度降低的价格提供胰岛素。 The program, part of the state’s broader effort to lower prescription drug costs, will offer the insulin at a significantly reduced price through select pharmacies and healthcare providers. 该倡议旨在打击高额胰岛素价格,支持病人管理糖尿病,特别是那些没有严格保险的糖尿病患者。 The initiative aims to combat high insulin prices and support patients managing diabetes, particularly those without robust insurance coverage. 预计该产品将于2026年初开始提供。 The product is expected to be available starting in early 2026.